联合治疗：市场看到的是侵蚀，而非补充——买入（纳斯达克：UTHR）
· seekingalpha.com
联合治疗的下跌是真实的，但这仅占业务的约32%，税后正常化盈利能力为10.5亿美元。了解为何UTHR股票目前值得买入。
United Therapeutics Corporation ( UTHR ) is down ~19% from its 52-week high of $609.35 because revenue declined for two consecutive quarters. Investors seem to ...